Aragen Bioscience has received three subcontracts to produce and characteriza stable cell lines expressing antibodies against polio virus, pandemic influenza virus and Candida albicans, and to develop cell culture and purification processes to produce the antibodies for preclinical studies.
NIAID principal investigator for the contract Jon Mirsalis said working together, they will advance promising therapeutics to the clinic.
Aragen president and CEO Rick Srigley said these novel antibodies represent the next generation in infectious disease treatment and they look forward to supporting this important work in developing these new therapies.